Sec Form 4 Filing - Droia Invest II SCSp @ Cyteir Therapeutics, Inc. - 2021-06-22

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Droia Invest II SCSp 2. Issuer Name and Ticker or Trading Symbol Cyteir Therapeutics, Inc. [ CYT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 28 BOULEVARD JOSEPH II 3. Date of Earliest Transaction (MM/DD/YY) 06/22/2021 (Street) LUXEMBOURG, N4L-1840 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/22/2021 C 3,259,026 A 3,259,026 D ( 2 ) Common Stock 06/22/2021 P 277,777 A $ 18 3,536,803 D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series B Convertible Preferred Stock ( 1 ) 06/22/2021 C 10,000,000 ( 1 ) ( 1 ) Common Stock 2,933,583 ( 1 ) 0 D ( 2 ) Series C Convertible Preferred Stock ( 1 ) 06/22/2021 C 1,109,368 ( 1 ) ( 1 ) Common Stock 325,443 ( 1 ) 0 D ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Droia Invest II SCSp 28 BOULEVARD JOSEPH II LUXEMBOURG, N4L-1840 X Wepaven BV BRUSSELSESTEENWEG 11 MEISE, C91860 X DF II GP Sarl 28 BOULEVARD JOSEPH II LUXEMBOURG, N4L-1840 X IHL SA 28 BOULEVARD JOSEPH II LUXEMBOURG, N4L-1840 X Verelst Luc 28 BOULEVARD JOSEPH II LUXEMBOURG, N4L-1840 X Naesens Janwillem 128 SPRING ST, BUILDING A, SUITE 510 LEXINGTON, MA02421 X Signatures Droia Invest II SCSp, By: DF II GP Sarl, By: /s/ Janwillem Naesens, Name: Wepaven BV (represented by Janwillem Naesens), Title: Manager 06/24/2021 Signature of Reporting Person Date DF II GP Sarl, By: /s/ Janwillem Naesens, Name: Wepaven BV (represented by Janwillem Naesens), Title: Manager 06/24/2021 Signature of Reporting Person Date Wepaven BV, By: /s/ Janwillem Naesens, Name: Janwillem Naesens, Title: Director 06/24/2021 Signature of Reporting Person Date IHL SA, By: /s/ Luc Verelst, Name: Luc Verelst, Title: Director 06/24/2021 Signature of Reporting Person Date Luc Verelst, By: /s/ Luc Verelst 06/24/2021 Signature of Reporting Person Date Janwillem Naesens, By: /s/ Janwillem Naesens 06/24/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. ( 2 )Shares held by Droia Invest II SCSp. DF II GP Sarl is the general partner of Droia Invest II SCSp. Wepaven BV (represented by Janwillem Naesens) and IHL SA (represented by Luc Verelst), the managers of DF II GP Sarl, share voting and investment power with respect to the shares held of record by Droia Invest II SCSp. Mr. Naesens, a member of the Issuer's board of directors, disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Luc Verelst disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.